Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 27, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Stewart Susan B. (Chief Regulatory Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.55	2030-12-29	Common Stock (33419)		Direct

Footnotes

F1: 25% of this option shall vest and become exercisable on November 1, 2021, with the remainder vesting in 12 substantially equal quarterly installment thereafter.